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Abstract 
Morphine is one of the most effective analgesics in medicine. However, its use is associated 
with the development of tolerance and dependence. Recent studies demonstrating epigenetic 
changes in the brain after exposure to opiates have provided insight into mechanisms possibly 
underlying addiction. In this study, we sought to identify epigenetic changes in ten regions of 
the rat brain following acute and chronic morphine exposure. We analyzed DNA methylation 
of six nuclear-encoded genes implicated in brain function (Bdnf, Comt, Il1b, Il6, Nr3c1 and 
Tnf) and three mitochondrially-encoded genes (Mtco1, Mtco2 and Mtco3), and measured 
global 5-methylcytosine (5-mc) and 5-hydroxymethylcytosine (5-hmc) levels. We observed 
differential methylation of Bdnf and Il6 in the pons, Nr3c1 in the cerebellum, and Il1b in the 
hippocampus in response to acute morphine exposure (all p<0.05). Chronic exposure was 
associated with differential methylation of Bdnf and Comt in the pons, Nr3c1 in the 
hippocampus and Il1b in the medulla oblongata (all p<0.05). Global 5-mc levels significantly 
decreased in the superior colliculus following both acute and chronic morphine exposure, and 
increased in the hypothalamus following chronic exposure. Chronic exposure was also 
associated with significantly increased global 5-hmc levels in the cerebral cortex, 
hippocampus and hypothalamus, but significantly decreased in the midbrain. Our results 
demonstrate, for the first time, highly localized epigenetic changes in the rat brain following 
acute and chronic morphine exposure. Further work is required to elucidate the potential role 
of these changes in the formation of tolerance and dependence. 
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Introduction 
Morphine is one of the most effective analgesic medications. It, along with other opioids, 
relieves acute and chronic pain by acting at mu opioid receptors found throughout the central 
nervous system. Alongside its therapeutic effects, morphine use is also associated with 
adverse effects such as tolerance and dependence. 
Morphine tolerance may originate in part through neuronal processes via activation of 
mu opioid receptors and subsequent neuroexcitation1. Preclinical gene expression profiling 
studies have demonstrated widespread changes in the transcriptome of the nucleus 
accumbens and striatum following chronic morphine exposure2,3, including to genes 
associated with circadian rhythms, neurotransmitter release, and glucocorticoid receptor 
signalling. There is also increasing evidence for a role of microglia in tolerance. Microglia 
are macrophages present within the central nervous system that produce pro-inflammatory 
cytokines such as interleukin 1E (IL-1E), interleukin 6 (IL-6) and tumor necrosis factor alpha 
(TNF-D) following their activation by morphine4. IL-1E, IL-6 and TNF-D have been shown 
to reduce morphine analgesia within five minutes of administration4, and blockade of IL-1E 
signalling prolongs morphine-induced analgesia5, thereby potentially implicating these three 
cytokines in morphine tolerance. Microglial activation is further implicated in the 
development of tolerance through increased expression of brain derived neurotrophic factor 
(BDNF) in the ventral tegmental area (VTA) that facilitates the switch to the dopamine-
dependent reward system present in addiction6. Notably, Bdnf -/- knockout mice do not 
develop tolerance to morphine7. Other genes implicated in morphine tolerance include the 
catechol-O-methyltransferase (COMT) gene through its role in dopamine elimination and 
whose activity therefore regulates morphine response in mice8, and the glucocorticoid 
receptor gene NR3C1 that is epigenetically silenced in the HPA axis following chronic, but 
not acute, morphine exposure9. 
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Exposure to opiates is also known to induce mitochondrial dysfunction in neuronal 
and glioma cells10,11, and chronic exposure is associated with reduced mitochondrial DNA 
copy number in the rat hippocampus12. Furthermore, morphine may induce oxidative stress in 
the brain13, and this is known to induce the expression of mitochondrial DNA 
methyltransferase 1 (mtDNMT1) that regulates the mitochondrial epigenome14. 
Morphine exposure has been demonstrated to affect the epigenetic regulation of genes 
implicated in addiction and tolerance, both in human studies and in animal models. 
Differential methylation of the BDNF15,16 and opioid receptor Mu 1 (OPRM1)17,18 gene 
promoters have been reported in the blood of opiate-dependent individuals. Epigenetic 
changes in the brain may be highly localized, as studies utilizing whole brain tissue have 
often reported no significant change in global DNA methylation levels following morphine 
exposure19,20. Targeted approaches have proven more insightful, identifying changes in 
regions of the brain associated with addiction such as the hippocampus, medial prefrontal 
cortex and VTA in a rat model of heroin self-administration and reward devaluation21 and 
post-mortem orbitofrontal cortex brain tissue from former heroin users22. 
However, there remains a significant knowledge gap regarding the spatial and 
temporal epigenetic regulation of genes in the brain that are implicated in tolerance and 
dependence. In this study, we analyzed epigenetic changes in response to acute and chronic 
morphine induction in 10 regions of the rat brain reported to be implicated in response to 
opiates and the formation of addiction:the midbrain contains the VTA that has been 
consistently implicated in addiction23,24; the pons contains the locus coeruleus that is key in 
the integration of opioid and stress signalling and which is served by innervation from the 
paraventricular nucleus of the hypothalamus25; the inferior and superior colliculus regulate 
response to opiate withdrawal through reduced activation of mu-opioid receptor 
signalling26,27; the cerebral cortex (containing the dorsomedial prefrontal cortex), 
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hippocampus and cerebellum are implicated in reinforcement of drug-seeking beheaviors28
30; the medulla oblongata is crucial in pain modulation and opiate withdrawal behaviors31; 
and the thalamus whose function is disrupted in opiate dependence32,33. We measured global 
5-methylcytosine and 5-hydroxymethylcytosine levels, and analyzed the DNA methylation of 
genes previously identified as implicated in morphine tolerance (Bdnf, Comt, Il1b, Il6, Nr3c1 
and Tnf) and mitochondrially-encoded genes potentially implicated in mitochondrial 
dysfunction (Mt-co1, Mt-co2, and Mt-co3). 
 
Results 
Study overview 
An overview of the study is provided in Figure 1. Male rats were assigned to control, acute 
challenge and chronic induction groups (all n=5). After 10 days, brain tissue was dissected 
and DNA extracted for epigenetic analysis. 
 
Gene-specific DNA methylation variability by region of the rat brain 
The nuclear-encoded genes Bdnf, Comt, Il1b, Il6, Nr3c1 and Tnf displayed differential 
variability by region of the brain (Figure 2A-F). Bdnf and Tnf displayed highly conserved 
methylation levels between the regions, with mean Bdnf methylation levels ranging between 
3.0 and 4.6% (Figure 2A), and Tnf methylation between 54.0 and 62.5% (Figure 2F). The 
greatest variability was observed in Il6 methylation, which displayed low levels (<6.5%) in 
the cerebellum, cerebral cortex and hippocampus, but markedly higher methylation (>20%) 
in the hypothalamus, inferior colliculus, superior colliculus, and the thalamus (Figure 2D). 
Global DNA methylation levels, estimated using LINE-1 as a surrogate marker (L1-5utr and 
L1-orf), were highly consistent between brain regions (Figure 2G-H). 
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Morphine induction is associated with gene-specific and global DNA methylation changes 
in the rat brain 
Acute morphine exposure (10 mg/kg, one hour post injection) was associated with 
significantly increased methylation of Il6 in the pons (11.6 vs 14.3%, p<0.05) and Nr3c1 in 
the cerebellum (1.0 vs 1.2%, p=0.03), and significantly decreased methylation of Bdnf in the 
pons (3.9 vs 3.3%, p=0.03) and Il1b in the hippocampus (76.5 vs 71.8%, p=0.02) (Table 2, 
Figure 3). Chronic morphine exposure (10 mg/kg/day bid for 10 days) was associated with 
significantly increased methylation of Il1b in the medulla oblongata (64.8 vs 68.4%, p=0.03) 
and Nr3c1 in the hippocampus (1.0 vs 1.6%, p=0.02), and significantly decreased 
methylation of Bdnf (3.9 vs 3.1, p=0.02) and Comt in the pons (77.3 vs 66.9%, p<0.0001). 
Global DNA methylation levels, estimated through measurement of Line1 
methylation, were significantly lower in the superior colliculus following both acute (L1-orf, 
82.5 vs 81.9%, p<0.05) and chronic morphine exposures (L1-orf, 82.5 vs 81.3%, p=0.003), 
and higher in the hypothalamus following chronic exposure (L1-5utr, 53.7 vs 54.9%, p=0.04) 
(Figure 4).  
 
Nuclear 5-hydroxymethylcytosine levels are altered following morphine induction 
We measured global 5-hydroxymethylcytosine (5-hmc) levels in each of the ten regions of 
the brain following acute and chronic morphine induction. In the control rats, 5-hmc levels 
varied by brain region (Table 2). The lowest levels of 5-hmc were observed in the 
hippocampus (0.34%) and thalamus (0.37%), with the highest in the midbrain (0.79%) and 
pons (0.69%). Significant changes in 5-hmc levels were identified following chronic 
morphine induction, but none following acute exposure. 5-hmc levels increased in the 
cerebral cortex (0.50% vs 0.78%, p=0.002), hippocampus (0.34% vs 0.43%, p=0.01) and 
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hypothalamus (0.40% vs 0.54%, p=0.008), while they decreased in the midbrain (0.79% vs 
0.36%, p<0.0001) (Figure 5). 
 
Morphine induction is not associated with alterations in DNA methylation of 
mitochondrially-encoded genes 
We measured DNA methylation of three mitochondrially-encoded genes (Mtco1, Mtco2 and 
Mtco3) following morphine exposure. Methylation levels of the three genes were uniformly 
low across the 10 brain regions, with mean levels ranging between 0.8 (Mtco2, cerebral 
cortex and pons) and 2.7% (Mtco1, cerebral cortex) (Table 3). No significant effect of acute 
or chronic morphine induction was observed on methylation of the three genes in any of the 
brain regions. The most substantial changes in methylation were observed for Mtco1 in the 
cerebral cortex following acute (2.7 vs 1.8%, p=0.23) and chronic (2.7 vs 1.9%, p=0.29) 
morphine induction. 
 
Discussion 
In this study, we investigated the effect of acute and chronic morphine exposures 
upon nuclear and mitochondrial DNA methylation in ten regions of the rat brain known to be 
affected by opiates. Brain region-specific changes were identified in global 5-methylcytosine 
and 5-hydroxymethylcytosine content, and the Bdnf, Comt, Il1b, Il6 and Nr3c1 genes in 
response to morphine exposure. We did not observe differential methylation within the 
mitochondrial genome. To our knowledge, our study is the first to identify region-specific 
epigenetic changes in the brain in response to morphine exposure. 
Morphine induces the dopaminergic mesolimbic pathway in the ventral tegmental 
area (VTA) within the midbrain. This region of the brain has a high concentration of 
dopaminergic neurons and is considered to be crucial in addiction. We observed significantly 
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decreased global DNA methylation in the superior colliculus, estimated through analysis of 
Line1, and a highly significant decrease in 5-hmc content in the midbrain. Together, these 
observations demonstrate substantial epigenetic changes in this important region of the brain 
with morphine exposure. 
5-hmc is approximately 10-fold more abundant in the brain than other tissues34, 
increasing during neuronal development but also implicated in age-related 
neurodegeneration.35 While 5-hmc is an intermediate in active DNA demethylation, 5-mc and 
5-hmc levels are not inherently correlated36 and therefore our observations of decreased 5-mc 
and 5-hmc are not contradictory. Furthermore, our results could also be the product of the 
direct role of 5-hmc in RNA splicing37 and gene expression through inhibition of chromatin 
remodelling38, which may offer an alternative explanation for our observations. TET1 has 
been demonstrated to be down-regulated in response to cocaine administration, leading to 
locus-specific decreases in 5-hmc.39 Whilst other studies have reported no change in global 5-
hmc content in response to heroin and cocaine exposure19,20,39, they have focussed upon a 
single region (nucleus accumbens) or utilized homogenized brain tissue and therefore could 
not exclude the possibility of localized changes in 5-hmc in specific regions of the brain. The 
limitations of such approaches were addressed in the current study. Indeed, a particular 
strength of this work is the analysis of ten different regions of the brain that has facilitated the 
identification of region-specific changes in DNA methylation. Our findings demonstrated 
significantly increased 5-hmc levels in the cerebral cortex, hippocampus and hypothalamus, 
in contrast to observations elsewhere of increased hippocampal 5-hmc levels following the 
cessation of cocaine.40 Further work is required to elucidate the functional implications of 
these observations. 
We identified differential methylation of three genes (Bdnf, Comt and Il6) in the pons 
following morphine exposure. This region, located inferior to the midbrain, regulates 
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respiration and sleep, which are commonly disturbed with morphine use. Animal studies have 
demonstrated a morphine-induced reduction in acetylcholine in the pons and medulla 
oblongata41, thereby further implicating this region in response to the drug. BDNF expression 
facilitates opiate-associated neural plasticity42 and the dopamine-dependent response to 
opiates.6 Chronic exposure to opiates is associated with increased BDNF levels in the VTA23, 
and it has been demonstrated that this increase begins rapidly after initial usage.43 Other 
studies have reported increased expression of BDNF in the VTA following morphine 
withdrawal.24 Our results provide further evidence for the role of BDNF in the acute response 
to morphine exposure and suggest that this may not be limited to the VTA. Catechol-O-
methyltransferase (COMT) is implicated in dopamine elimination, and subsequently COMT 
activity reduces response to morphine8, while genetic variants in the COMT gene are 
associated with differential response to morphine as an analgesic.44 Our observation of 
decreased Comt methylation with chronic exposure may be in response to increased 
dopamine signalling and a role in its catabolism. The changes seen in Il6 in the pons may be 
in accordance with the modulating role that opioids have in inflammatory pathways45. Our 
observation of increased Il6 promoter methylation is in contrast to reports of increased 
secretion in acute response to morphine in the spinal cord4 and plasma46,47. Notably, however, 
we also identified regional-specificity in Il6 methylation levels, and therefore the difference 
in measured methylation levels may represent alterations in cell composition, such as 
increased microglial infiltration. As IL-1E and TNF-D are also secreted by activated 
macrophages in response to morphine48, but were not differentially methylated in the pons, it 
is unclear how IL-6 alone may be implicated in response to morphine. 
Morphine administration can induce the generation of reactive oxygen species (ROS) 
by increasing the metabolism of substrates such as dopamine and xanthine oxidase.49 
Elevated ROS levels are known to induce site-specific alterations in DNA methylation by 
11

mechanisms such as modulation of the expression of DNA methyltransferases (DNMTs).50 
While the observed gene-specific changes in DNA methylation are likely to be directly 
induced by morphine administration, global changes in 5-mc and 5-hmc content could in part 
be non-specific effects through increased ROS production. 
The study of the mitochondrial epigenome is an emerging field of interest. Alterations 
in mitochondrial DNA methylation have been demonstrated in cardiovascular disease51 and 
in response to environmental exposures.52,53 It has been speculated that such epigenetic 
changes may give rise to the altered mitochondrial function observed in drug addiction.14 
However, our study did not identify differential methylation of mitochondrial genes in 
response to morphine induction. We cannot exclude the possibility that other regions of the 
mitochondrial epigenome may be differentially methylated in response to exposure, and 
therefore more comprehensive analysis is required. 
Our study contains certain limitations that restrict the inferences that can be made 
from our observations. In particular, the absence of rat behavioral studies and the lack of 
RNA and protein samples to analyze gene expression have precluded the study of the 
functional impact of the observed epigenetic changes. The number of cells obtained from 
some of the dissected tissue specimens was only sufficient to extract DNA from, and 
therefore no analysis of gene expression was possible. Gene-specific analysis of 5-hmc 
content could also have proven highly insightful, but is currently prohibitively expensive. 
Nonetheless, our study offers several important strengths. Firstly, the study of ten different 
regions of the brain has enabled us to identify region-specific epigenetic changes in response 
to drug exposure. Furthermore, we have performed a range of epigenetic analyses (nuclear 
and mitochondrial gene-specific DNA methylation, global 5-mc and 5-hmc content) that have 
facilitated a broader study of the epigenome in response to morphine exposure. Finally, our 
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study design has enabled the delineation of epigenetic changes associated with acute and 
chronic morphine exposure. 
In conclusion, we have identified gene-specific and global changes in DNA 
methylation in response to acute and chronic morphine exposure, which were highly 
localized to specific regions of the brain. Of especial interest, we identified significant 
changes in 5-hmc content in four of the ten regions, suggestive of wider epigenetic 
remodelling in response to morphine exposure. It is hoped that our findings will help to 
inform further studies in the treatment of dependence, including elucidation of the functional 
consequences of the observed epigenetic changes and how they relate to long-term response 
to opiates. Additionally, our findings may help to facilitate the production of biomarkers of 
drug tolerance. Given the increases in deaths from opiate overdose within the past decade54,55, 
there is an urgent clinical need for tolerance biomarkers that could help to reduce thousands 
of avoidable deaths. 
 
Materials and Methods 
Animals and Housing Conditions 
Male Wistar rats (180-200 g) were purchased from Shanghai Laboratory Animal Center 
(Shanghai, China). Following shipment, rats were housed in a temperature- (22-24 ƕC) and 
humidity- (60%) controlled environment on a 12-hour light/dark cycle (lights on at 7:00 AM) 
for three days to allow for acclimatization prior to experimental studies. The animals were 
given free access to food and water ad libitum. All efforts were made to reduce the number of 
animals used and to minimize their suffering. Experimental study groups were assigned 
randomly. All procedures were approved by the Laboratory Animal Use Committee of 
Shanghai Jiao Tong University School of Pharmacy. 
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Drugs 
Morphine hydrochloride was purchased from Shenyang First Pharmaceutical Co., Ltd. 
(Shenyang, Liaoning, China) and Maybridge Chemicals (Cornwall, U.K.). CBIO was freshly 
dissolved in sterile normal saline solution (Sinopharm Group Chemical Reagent Co., Ltd.) 
with the pH adjusted to 7.3-7.5 with 1 M NaOH solution. 
 
Morphine induction 
Male rats were assigned into three groups (each n=5) receiving alternative treatment 
regimens: saline/saline (Group A, control); saline/morphine (Group B, acute challenge, 10 
mg/kg); and morphine/morphine (Group C, chronic induction). For morphine chronic 
induction, the first treatment period consisted of subcutaneous injection of saline (Groups A 
and B, 10 ml/kg) or morphine (Group C, 10 mg/kg) twice daily at 12-hour intervals for nine 
consecutive days56. On Day 10, the second treatment was performed by a single subcutaneous 
injection of saline (Group A) or morphine (Groups B and C, 10 mg/kg) (Figure 1). Previous 
work has demonstrated tolerance to morphine is developed within 7-10 days, with epigenetic 
changes observable in the rodent brain 5-7 days following first treatment57,58. 
 
Sample Preparation and DNA Extraction 
The rats were decapitated on Day 10, one hour after the last administration. Brains were 
removed from the skull and ten brain regions (cerebellum, cerebral cortex, hippocampus, 
hypothalamus, inferior colliculus, midbrain, pons, medulla oblongata, superior colliculus and 
thalamus) were rapidly dissected, frozen on dry ice, and kept at -80°C until processed. DNA 
was extracted from the tissues using the Wizard Genomic DNA purification kit (Promega, 
Madison, WI) according to the manufacturers instructions. Purified DNA was stored at -
20°C until analysis.  
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DNA Methylation Analysis 
Gene-specific and global 5-mc DNA methylation were analyzed by pyrosequencing. Global 
methylation levels were estimated using two assays to interrogate Line1 methylation (L1-utr 
and L1-orf) that have been widely utilized for this purpose since their first development59 and 
which correlate well with measures of global 5-mc content by high-performance liquid 
chromatography60. Gene-specific assays were designed to interrogate promoter regions for 
the Bdnf, Comt, Il1b, Il6, Nr3c1 and Tnf genes. Specifically, the assays interrogated Bdnf 
promoter IV that influences response to levomethadone15, tbe Comt P1 promoter that 
regulates expression of the shorter tissue-specific S-COMT isoform that influences dopamine 
metabolism in the mouse brain61, and the Nr3c1 GR110 promoter that we have previously 
demonstrated to be differentially methylated in the rat brain in response to environmental 
exposures62. 
Bisulfite conversion was performed using 1 µg of genomic DNA and the EZ-96 DNA 
Methylation-Gold Kit (Zymo Research, Orange, CA, USA) according to the manufacturers 
protocol. 30 µl M-Elution Buffer was used for the elution of bisulfite-converted DNA. 
Following amplification of target regions by polymerase chain reaction (PCR), DNA 
methylation was analyzed by pyrosequencing. Details of the primers and thermocycling 
conditions are shown in Table 1. In brief, a 30 µl-PCR was carried out using 15 µl GoTaq 
Hot Start Green Master Mix (Promega, Madison, WI), 10 pmol forward primer, 10 pmol 
reverse primer, 1 µl bisulfite-treated DNA, and water. Pyrosequencing was performed using 
the PyroMark Q96 MD Pyrosequencing System (QIAGEN, Germantown, MD). The 
percentage of methylated cytosines was quantified at three CpG sites for Bdnf, two for Comt, 
two for Il1b, one for Il6, six for Nr3c1, one for Tnf, two for L1-utr and one for L1-orf. For the 
mitochondrially-encoded genes, the percentage-methylation was measured at three CpG sites 
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for each of Mtco1, Mtco2 and Mtco3. Pyrosequencing reactions were performed in duplicate 
and the mean of the replicates taken forward for analysis. The correlation coefficient between 
replicate pyrosequencing runs ranged from 0.77 (L1-orf) to 0.97 (Comt). 
 
Analysis of global 5-hydroxymethylcytosine levels 
5-hydroxymethylcytosine was measured in total DNA using the MethylFlash Global DNA 
Hydroxymethylation ELISA Easy Kit (Epigentek) according to the manufacturers protocol. 
The correlation coefficient between replicates was 0.97. 
 
Statistical Analysis 
Analysis was performed using GraphPad Prism version 7.0b. Differences in DNA 
methylation were determined by t-test, with significance defined as p<0.05. 
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Figure legends 
Figure 1. Overview of experimental approach.  
Rats were assigned to control (A), acute morphine challenge (10 mg/kg one hour post 
injection, B) and chronic morphine induction (10 mg/kg/day bid for 10 days, C) groups. 
Saline or morphine were administered twice daily until tissue collection at Day 10. 
 
Figure 2: Variation in DNA methylation by region of the rat brain. A-F: DNA methylation of 
Bdnf, Comt, Il1b, Il6, Nrc31 and Tnf in the cerebellum (Ce), cerebral cortex (CE), 
hippocampus (Hi), hypothalamus (Hy), inferior colliculus (IC), medulla oblongata (MO), 
midbrain (Mi), pons (Po), superior colliculus (SC), and thalamus (Th). G-H: global DNA 
methylation estimated by measurement of L1-5utr and L1-orf elements in the same 10 
regions of the brain. 
 
Figure 3: Differential gene-specific DNA methylation in response to morphine exposure. 
Gene-specific changes in DNA methylation by morphine exposure (control, acute and 
chronic) are illustrated, with significant differences indicated (* = p<0.05, ** = p<0.01, *** = 
p<0.001; **** = p<0.0001). 
 
Figure 4: Global DNA methylation levels following acute and chronic morphine exposure. 
Global DNA methylation levels were estimated through measurement of L1-5utr and L1-orf 
elements in 10 regions of the rat brain. Regions displaying significant changes are illustrated 
(* = p<0.05, ** = p<0.01, *** = p<0.001; **** = p<0.0001). 
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Figure 5: Global 5-hydroxymethylcytosine levels following acute and chronic morphine 
exposure. Global 5-hmc levels were measured by ELISA in 10 regions of the rat brain, with 
significant changes illustrated (* = p<0.05, ** = p<0.01, *** = p<0.001; **** = p<0.0001). 
 
Table 1: PCR and pyrosequencing primer sequences. 
 
Table 2: Nuclear DNA methylation in the rat brain following morphine induction. Mean 
DNA methylation levels of six genes (Bdnf, Comt, Il1b, Il6, Nr3c1 and Tnf), global DNA 
methylcytosine (L1-5utr and L1-orf) and global 5-hydroxymethylcytosine (5-hmc) are 
provided for the 10 regions of the rat brain that were analyzed, with standard error of the 
mean in brackets. 
 
Table 3: DNA methylation of mitochondrial-encoded genes in the rat brain following 
morphine induction. Mean DNA methylation levels of three genes (Mtco1, Mtco2 and Mtco3) 
are provided, with standard error the mean in brackets.
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Figure 1. Overview of experimental approach 
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Figure 2: Variation in DNA methylation by region of the rat brain 
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Figure 3: Differential gene-specific DNA methylation in response to morphine exposure 
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Figure 4: Global DNA methylation levels following acute and chronic morphine exposure 
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Figure 5: Global 5-hydroxymethylcytosine levels following acute and chronic morphine exposure 
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Table 1: PCR and pyrosequencing primer sequences 
Gene name Primer Sequence 
Bdnf 
Forward primer (5' to 3') TTTTTAGTTTTTGTTTAGATTAAATGGAGT 
Reverse biotin primer (5' to 3') CAACAAAAAAATTAAATTATTAATAATAAA 
Sequencing primer (5' to 3') GTTTTTTATTGAAGG 
Sequence analyzed C/TGTGC/TGAGTATTATTTTC/TGTTATG 
Comt 
Forward primer (5' to 3') GTTTGTTGTAGTTTGGAGTTAGGT 
Reverse biotin primer (5' to 3') CTCATCCTCCCCCATTACCT 
Sequencing primer (5' to 3') TATGGTTTAGTGTGG 
Sequence analyzed C/TGGTTGTGGGGTGTAGGGGGC/TGGGGGGGT 
   
Nr3c1 
Forward primer (5' to 3') GGTTGGTAAAAGTTTGTTAAGTT 
Reverse biotin primer (5' to 3') CTAAAAACTCTCCCCTCCCC 
Sequencing primer (5' to 3') GTTTATTTTAGTATT 
Sequence analyzed C/TGC/TGC/TGTTC/TGTTC/TGTTC/TGC 
Il1b 
Forward primer (5' to 3') TGTATAAGGAAGTTTGATTGGAGAG 
Reverse biotin primer (5' to 3') ATAAAATCAATTAACCCAAAAAAAA 
Sequencing primer (5' to 3') ATGTTTTGAATTATT 
Sequence analyzed C/TGGGGTTTGCTGTCCACTAGTTTTCTCTCCCTC/TGTTTTA 
Il6-1 
Forward primer (5' to 3')  TTGTGATTTTTTGGATGTTAAATGA 
Reverse biotin primer (5' to 3') CAAACATCCCCAATCTCATATTTAT 
Sequencing primer (5' to 3') TTGTGATTTTTTGGATGTTAAATGA 
Sequence analyzed C/TGTTATAT 
Il6-2 
Forward primer (5' to 3')  TTGTGATTTTTTGGATGTTAAATGA 
Reverse biotin primer (5' to 3') CAAACATCCCCAATCTCATATTTAT 
Sequencing primer (5' to 3') TTAAAAGTAGAGAGT 
Sequence analyzed C/TGATTTTTA 
Tnf 
Forward primer (5' to 3') GGATTGTTATAGAATTTTGGTGAGG 
Reverse biotin primer (5' to 3') ACTTCCTTAATAAAAAAAACCATAATCTC 
Sequencing primer (5' to 3') TTAAATTTTTGTTTT 
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Sequence analyzed C/TGTATTGGAGAAGAAATTGA 
 
MT-co1 
 
Forward primer (5' to 3') AGTTGGAGTTGGAATAGGATGAATA 
Reverse biotin primer (5' to 3') TAACTCCTAAAATAAAAAACACCCC 
Sequencing primer (5' to 3') ATATTTTTTTTTAGT 
Sequence analyzed C/TGGAAATTTAGTTTATGTTGGGG/ATATTC/TGTAGATTTAA 
 
MT-co2 
 
Forward primer (5' to 3') TAATGATTTAAAATTAGGTGAATTT 
Reverse biotin primer (5' to 3') TAACCCTAATAAAAAAATAACTCATAAATA 
Sequencing primer (5' to 3') ATAGAATTTTTAATT 
Sequence analyzed C/TGTATATTAATTTTATTC/TGAAGAC/TGTTTTG 
 
MT-co3 
 
Forward primer (5' to 3') GTTATTATATTTTTATTGTATAAAAAGGTT 
Reverse biotin primer (5' to 3') AAATAATAAAATACTCAAAAAAATCC 
Sequencing primer (5' to 3') GTATAAAAAGGTTTT 
Sequence analyzed C/TGATAC/TGGAATAATTTTGTTTATTGTTTTC/TGAAGT 
L1 UTR 
Forward primer (5' to 3') GGTGTATAGGTTTTTTTGGTTGTTG 
Reverse biotin primer (5' to 3') AAATTCACCAAACAACTTTCTTACAA 
Sequencing primer (5' to 3') TTTTTTTGGTTGTTGT 
Sequence analyzed C/TGTTGTAGAGAGTTC/TGTGGTAGTATTTTA    
L1 ORF 
Forward primer (5' to 3') AGAAAGAATATTAAAAATAGTAAGGGAAAA 
Reverse biotin primer (5' to 3') ATCAATCCAAAATCTTCTAACCTTC 
Sequencing primer (5' to 3') TTATATTAGATTTTT 
Sequence analyzed C/TGTTAGAAATTAT 
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Table 2: Nuclear DNA methylation in the rat brain following morphine induction 
Region Treatment Bdnf Comt Il1b Il6-1 Nr3c1 Tnf L1-5utr L1-orf 5-hmc 
Cerebellum 
Control 3.0 (0.2) 82.5 (0.3) 64.2 (0.7) 6.3 (0.2) 1.0 (0.0) 62.5 (2.2) 53.3 (0.1) 80.4 (0.5) 0.48 (0.07) 
Acute 3.0 (0.2) 83.6 (0.5) 66.2 (1.3) 5.9 (0.3) 1.2 (0.1) 63.2 (2.8) 53.8 (0.3) 82.9 (0.3) 0.51 (0.06) 
Chronic 3.5 (0.4) 82.4 (0.3) 64.8 (0.4) 6.0 (0.2) 1.1 (0.2) 65.3 (0.9) 53.5 (0.1) 82.4 (0.2) 0.63 (0.03) 
Cerebral cortex 
Control 3.8 (0.2) 75.8 (1.3) 74.1 (0.7) 5.5 (0.2) 5.7 (1.7) 56.4 (1.3) 53.7 (0.4) 79.7 (0.5) 0.50 (0.06) 
Acute 4.1 (0.4) 74.8 (0.9) 76.1 (1.0) 8.2 (1.8) 3.1 (1.4) 55.3 (1.4) 53.3 (0.2) 80.0 (0.7) 0.54 (0.03) 
Chronic 3.8 (0.4) 77.5 (0.5) 74.6 (2.2) 5.5 (0.5) 4.7 (0.9) 52.8 (1.2) 53.6 (0.2) 79.3 (0.7) 0.78 (0.03) 
Hippocampus 
Control 4.3 (0.4) 72.4 (1.0) 76.5 (1.3) 6.5 (0.4) 1.0 (0.1) 57.1 (1.0) 54.8 (0.6) 82.2 (0.2) 0.34 (0.02) 
Acute 3.5 (0.2) 70.0 (1.1) 71.8 (1.0) 5.7 (0.5) 1.2 (0.1) 57.5 (1.8) 53.7 (0.2) 83.2 (0.2) 0.35 (0.01) 
Chronic 3.4 (0.2) 71.9 (0.2) 74.8 (0.7) 6.4 (0.3) 1.6 (0.2) 58.9 (1.0) 54.0 (0.4) 82.5 (0.2) 0.43 (0.01) 
Hypothalamus 
 
Control 3.6 (0.1) 65.1 (0.8) 70.1 (0.9) 21.8 (1.1) 1.1 (0.1) 59.4 (1.5) 53.6 (0.5) 81.1 (0.2) 0.40 (0.02) 
Acute 3.8 (0.2) 65.2 (1.5) 68.9 (2.1) 16.4 (2.7) 1.3 (0.2) 55.9 (1.4) 54.0 (0.6) 81.5 (0.4) 0.46 (0.02) 
Chronic 3.7 (0.3) 65.0 (0.8) 68.0 (1.2) 20.4 (0.9) 1.1 (0.1) 58.9 (1.1) 54.3 (0.7) 83.4 (0.3) 0.54 (0.03) 
Inferior colliculus 
Control 4.6 (0.3) 73.4 (0.5) 71.1 (3.4) 23.0 (0.5) 1.2 (0.2) 62.0 (2.1) 54.5 (0.5) 82.6 (0.1) 0.57 (0.1) 
Acute 3.9 (0.4) 72.6 (0.9) 72.4 (3.8) 22.5 (1.2) 1.3 (0.1) 62.5 (1.7) 54.2 (0.4) 80.0 (0.5) 0.62 (0.07) 
Chronic 4.0 (0.4) 72.7 (0.5) 76.1 (0.7) 24.0 (0.5) 1.3 (0.1) 63.7 (1.3) 53.6 (0.6) 77.5 (2.2) 0.79 (0.04) 
Medulla oblongata 
Control 3.7 (0.4) 69.8 (2.3) 64.8 (1.1) 13.7 (1.4) 1.0 (0.1) 54.0 (1.5) 53.4 (0.3) 80.1 (0.5) 0.51 (0.05) 
Acute 3.4 (0.3) 69.1 (1.1) 65.7 (3.6) 13.2 (0.9) 1.1 (0.1) 53.0 (1.5) 54.5 (0.6) 81.8 (0.2) 0.56 (0.07) 
Chronic 3.8 (0.2) 67.3 (0.8) 68.4 (0.9) 14.6 (0.3) 0.9 (0.1) 56.5 (0.4) 53.9 (0.4) 82.7 (0.1) 0.66 (0.08) 
Midbrain 
Control 3.3 (0.1) 66.8 (0.9) 76.6 (1.7) 18.8 (1.8) 1.8 (0.5) 58.8 (1.7) 55.4 (0.6) 81.9 (0.2) 0.79 (0.05) 
Acute 3.7 (0.4) 68.1 (1.1) 72.0 (1.8) 19.3 (0.9) 1.9 (0.4) 57.2 (1.8) 53.3 (0.4) 81.8 (0.4) 0.72 (0.03) 
Chronic 3.2 (0.3) 68.2 (1.0) 73.6 (2.0) 21.3 (1.2) 1.6 (0.3) 60.6 (2.1) 54.6 (0.7) 80.7 (0.1) 0.36 (0.01) 
Pons 
Control 3.9 (0.2) 77.3 (1.1) 74.3 (0.7) 11.6 (0.9) 3.9 (1.1) 55.5 (0.6) 53.6 (0.4) 83.1 (0.3) 0.69 (0.09) 
Acute 3.3 (0.1) 71.6 (2.7) 75.0 (1.4) 14.3 (0.7) 3.6 (0.8) 54.3 (1.1) 53.8 (0.3) 82.3 (0.1) 0.58 (0.05) 
Chronic 3.1 (0.2) 66.9 (0.8) 72.5 (1.6) 12.8 (1.4) 3.7 (1.1) 56.6 (2.5) 54.9 (0.3) 78.5 (0.2) 0.57 (0.06) 
Superior colliculus 
Control 3.7 (0.2) 74.8 (0.4) 60.3 (4.7) 24.6 (1.4) 1.2 (0.2) 57.0 (2.1) 53.9 (0.4) 79.7 (0.3) 0.54 (0.04) 
Acute 3.3 (0.3) 73.4 (1.8) 59.4 (3.6) 21.4 (1.8) 1.8 (0.5) 57.9 (1.6) 53.9 (0.3) 79.0 (0.2) 0.53 (0.03) 
Chronic 3.2 (0.3) 74.1 (0.7) 58.4 (2.2) 25.1 (0.6) 1.2 (0.1) 60.8 (1.1) 53.6 (0.0) 81.9 (0.2) 0.51 (0.03) 
35

Thalamus 
Control 3.6 (0.2) 67.7 (0.6) 73.5 (0.8) 21.0 (2.0) 1.7 (0.3) 57.7 (1.1) 54.4 (0.3) 82.8 (0.1) 0.37 (0.01) 
Acute 3.4 (0.1) 67.1 (1.0) 72.9 (2.4) 20.1 (2.2) 1.8 (0.4) 57.9 (2.4) 54.7 (0.1) 81.3 (0.2) 0.36 (<0.01) 
Chronic 3.6 (0.3) 67.9 (0.8) 72.2 (1.0) 22.2 (0.8) 2.0 (0.4) 60.1 (1.3) 53.5 (0.2) 81.7 (0.4) 0.37 (<0.01) 

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Table 3: DNA methylation of mitochondrial-encoded genes in the rat brain following 
morphine induction 
 
Region Treatment Mtco1 Mtco2 Mtco3 
Cerebellum 
Control 2.1 (0.1) 0.9 (0.1) 1.1 (0.1) 
Acute 2.0 (0.2) 1.0 (0.1) 1.2 (0.1) 
Chronic 2.1 (0.1) 0.9 (0.1) 1.1 (0.1) 
Cerebral cortex 
Control 2.7 (0.6) 0.8 (0.1) 1.1 (0.1) 
Acute 1.8 (0.3) 0.9 (0.2) 1.1 (<0.01) 
Chronic 1.9 (0.4) 0.8 (0.1) 1 (0.1) 
Hippocampus 
Control 1.9 (0.1) 1.0 (0.1) 1.2 (0.1) 
Acute 1.9 (0.2) 0.8 (0.1) 1.3 (0.1) 
Chronic 1.8 (0.1) 0.8 (0.1) 1.1 (0.1) 
Hypothalamus 
 
Control 2.0 (0.1) 0.9 (0.1) 1.1 (0.1) 
Acute 2.1 (0.2) 0.9 (0.1) 1.1 (0.1) 
Chronic 1.9 (0.2) 0.7 (0.1) 1.0 (0.1) 
Inferior colliculus 
Control 2.2 (0.1) 1.0 (0.1) 1.3 (0.2) 
Acute 2.2 (0.1) 0.9 (0.1) 1.2 (0.1) 
Chronic 2.0 (0.1) 0.8 (0.1) 1.1 (0.1) 
Medulla oblongata 
Control 2.4 (0.3) 1.0 (0.1) 1.1 (0.1) 
Acute 2.0 (0.2) 0.8 (0.1) 1.1 (0.1) 
Chronic 2.0 (0.2) 0.8 (0.1) 1.1 (0.1) 
Midbrain 
Control 1.9 (0.2) 0.9 (0.1) 1.2 (0.2) 
Acute 2.2 (0.4) 0.9 (0.1) 1.1 (0.1) 
Chronic 2.0 (0.2) 1.0 (0.1) 1.1 (0.1) 
Pons 
Control 1.9 (0.3) 0.8 (0.1) 1.0 (0.2) 
Acute 2.3 (0.4) 0.8 (0.1) 1.6 (0.5) 
Chronic 2.6 (1.0) 0.8 (0.1) 1.1 (0.1) 
Superior colliculus 
Control 2.1 (0.1) 1.0 (0.1) 1.3 (0.1) 
Acute 2.4 (0.2) 0.8 (0.1) 1.3 (<0.01) 
Chronic 2.1 (0.2) 0.9 (0.1) 1.3 (0.1) 
Thalamus 
Control 2.1 (0.1) 1.0 (0.1) 1.3 (0.2) 
Acute 1.9 (0.1) 0.9 (0.1) 1.1 (<0.01) 
Chronic 1.8 (0.2) 1.0 (0.3) 0.9 (0.1) 

